IDOR-1117-2520 is now in a Phase 2 proof-of-concept trial in psoriasis, with the potential to expand into additional autoimmune conditions where the CCR6-CCL20 pathway plays a pathogenic role.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback